Airfinity Ltd

Airfinity was invited to give an exclusive briefing at The White House on the rising threat of infectious disease outbreaks. Speaking to Dr. Paul Friedrichs and members of the Office for Pandemic Preparedness and Response Policy and the National Security Council, The White House, CEO Rasmus Bech Hansen and VP of Biorisk Michelle Holko presented our latest analysis on the most imminent threats to the United States, including the detection of avian #influenza in US mammalian livestock, the impact of reduced #vaccine uptake on #measles cases, and #mpox clade IIb and clade I outbreaks. Airfinity uses AI-augmented simulations and forecasts to enable better risk assessment and earlier warning systems that support health, security, and defense goals for multiple G7 governments. To organise a briefing for your team, email us directly at contact@airfinity.com. 

Tomorrow, Airfinity’s VP of Biorisk, Michelle Holko, and Director of Federal Business, Jennings Heussner, will attend Biomedical Advanced Research and Development Authority (BARDA) Innovation Symposium in Washington, DC. Our featured poster, Improving Global Health Security through Data-Driven Analysis and Forecasting, reveals critical insights from our recent analysis with Bloomberg. The data highlights post pandemic surges in #outbreaks of #diseases like measles, whooping cough, tuberculosis, polio, dengue, and cholera worldwide. This year alone, vector-borne priority pathogens have comprised 60% of total priority pathogen activity, a trend likely to grow as climate change intensifies. Anticipating the timeline, geographic spread, and burden of these diseases is essential for prioritising medical countermeasure development, deployment, and other health security interventions. Curious about the implications and ways to mitigate these risks? Connect with Michelle and Jennings at the conference, or reach out to infectiousdiseases@airfinity.com for more information. https://lnkd.in/gWfKr5nj

Airfinity’s Henrik Sillesen is quoted in today’s article on the potential of #Amylin, and Novo Nordisk’s candidate #CagriSema, to change the global weightloss treatment market. “After GLP-1, GIP and glucagon, amylin is the next-biggest target being explored for weight loss. Positive results from Novo Nordisk’s Phase 3 REDEFINE on CagriSema, will solidify amylin as a viable anti-obesity therapeutic target. The expectation is that amylin-targeting compounds might elicit fewer gastrointestinal-related side effects than seen with GLP-1 drugs, like Wegovy. CagriSema may not only just validate amylin as a target, but also highlights the potential for combination therapies of amylin and existing anti-obesity medications, which may boost overall achievable weight loss. This might impact the strategy behind the pipeline of amylin compounds, where pharma may opt to position their amylin assets as additive to GLP-1s.” If you have question or would like to find our more about Airfinity’s obesity market intelligence solution, email us at obesity@airfinity.com.

Pfizer has raised its full 2024 revenue guidance for #Paxlovid, its #COVID-19 antiviral, to $5.5 billion, aligning closely with Airfinity’s July forecast of $5.47 billion (within a range of $4.33 to $6.78 billion). Airfinity’s data-driven forecasts have consistently monitored the demand for COVID-19 oral antivirals in 2024, using an SIR model to forecast COVID-19 levels, coupled with the depletion of pandemic stockpiles and demand from key countries. While initially estimating a need for 8 million courses, this was revised to 7.1 million in July. Despite the transition from government advanced purchasing to standard commercial purchasing seen in 2024, utilisation of Paxlovid has remained stable, especially in the US. COVID-19 levels did not decline substantially in 2024, reinforcing these revised revenue expectations. To learn more about our forecast reach out to infectiousdiseases@airfinity.com.

Airfinity’s Sam Cutler presented disease modelling predicting dengue cases in Peru at the American Public Health Association (APHA) conference in Minneapolis yesterday. It shows the potential of meteorological data being integrated into epidemiological models as a low-cost, early warning system for dengue-endemic countries increasingly affected by weather events brought on by climate change. In a world where climate is becoming more impactful on disease dynamics, being able to predict these events is crucial for better public health preparedness. Our predictions show a 7% error margin for reported #dengue cases between July and December 2023, with approximately a two percent difference in July 2024 at the end of our 12-month forecast. If you are interesting in learning more about our modelling capabilities, please reach out to us at infectiousdisease@airfinity.com

Weightloss drugs have the potential to change the world’s health, habits and happiness with profound consequences for the global economy and society. The Economist’s cover story this week is essential reading for those curious about the drugs' potential and impact in the years to come. As featured in the article, Airfinity’s pipeline tracker shows the number of new drugs in late-stage clinical trials, a number which has almost doubled since January. Airfinity’s obesity intelligence solution provides insights on both the clinical and commercial landscapes helping clients navigate the evolving market through data simulations and predictive modelling. If you’d like to find out more, email us at obesity@airfinity.com https://lnkd.in/g6nh9BwN

That's a wrap for #IDWeek2024! A big thank you to everyone who visited the Airfinity booth and connected with our team. The conference was packed with valuable insights, and we were excited to see some late breaking data. A key highlight was the new Phase IIb/III data on Merck's monoclonal antibody candidate, clesrovimab. The results showed that a single dose of clesrovimab offers protection against mild, moderate, and severe #RSV in infants, both preterm and full-term. We anticipate Merck may file for U.S. approval by the end of Q4, potentially gaining approval before the 2025/26 season if a priority review voucher is used. Clesrovimab's fixed dose strategy and high efficacy against mild RSV may place clesrovimab as an important alternative to nirsevimab and help address supply shortages. For more insights or a detailed recap of the conference, feel free to reach out to us at infectiousdiseases@airfinity.com.

Airfinity is attending IDWeek in Los Angeles! Our analyst Zainab Riyaz is presenting a poster titled “The Potential Impact of Vaccination on Clade I Mpox Cases in the Democratic Republic of Congo, and Risk of Importation to the United States from International Travel.” Our Chief Product Officer Jon Moser, Senior Director of Custom and Analytics Arsalan A., Commercial Director Haroon Ahmed and Business Development Manager Ane Altuna Oses are all attending. If you would like to meet the team, or discuss how our modeling and forecasting can support your organisation, drop by and say hello at Booth 119.

Will bird flu be the next #pandemic? How widespread is the #H5N1 spillover in US cattle? Could the virus be circulating in other animals and is it time to start vaccinating animals and people? If you missed our webinar last week, you can listen to our expert panel discuss these questions and more using the link below. Our panel brought together Hanna Nohynek, Chief Physician at the Finnish Institute for Health and Welfare, Angela Rasmussen, a virologist at the Vaccine and Infectious Disease Organization at the University of Saskatchewan in Canada, Florian Krammer, Professor at Icahn School of Medicine at Mount Sinai, Bob Kadlec, former Assistant Secretary of Preparedness and Response at the U.S. Department of Health & Human Services (HHS) and our own Michelle Holko, VP of Biorisk at Airfinity. https://lnkd.in/e77_CkBQ

Look forward to taking part in the World Health Summit in Berlin in the coming days. The obvious challenge facing all participants is that too many people are suffering and dying from perfectly preventable diseases. Health systems world wide are still reeling from the pandemic and many places stretched beyond capacity. There is certainly no single simple solution. But in every health system there are thousands of small fixes that can be implemented to move from costly treatments towards preventions. These fixes range from an overhaul of diagnostics to more intelligent use of a broad range health data signals to guide interventions. More targeted vaccination campaigns and better use of the new generation of "pre-emptive" drugs could also make a big difference. And when it comes to  access to vaccine and medicine, there are ways to incentivise innovation and risk taking, but also ensure a rapidly reduced cost curve for low and middle income countries (and households). The list is long and that's reason for hope. Ping me if you are around and interested in discussing how to save lives and reduce health care cost through better preventations.